Charting Excellence Canada’s Top 5 Pioneers in Biotech 1.pdf

December | Issue 02 | 2023
Minds and Machines
A Symbiotic
Relationship in
Biotech Innovation
From Lab to Market
The Business of
Biotech Startups
Michael Gareau
Founding President
Starpax Biopharma Inc.
Charting Excellence:
Canada’s Top 5
Pioneers in
Biotech
Starpax
Biopharma Inc.
Solving a Problem of Resistance to Cancer Treatment that
Chemotherapy and Immunotherapy have Never Solved

Canada’s Top 5
Pioneers in
Biotech

n the landscape of scientific progress, biotechnology
Istands as a key player, offering solutions to some of
humanity’s most pressing challenges. Biotech is
pivotal in shaping our future, from healthcare
breakthroughs to sustainable agriculture. In the vast
expanse of Canada, this dynamic field is not just a scientific
endeavor; it’s a driving force behind innovation and
progress.
Biotechnology encompasses the use of biological processes,
organisms, or systems to advance new technologies or
products that benefit society. Its significance is profound,
ranging from advancing medical treatments and diagnostics
to addressing environmental concerns and enhancing
agricultural practices. Biotech is a hub in the quest for
solutions to complex global issues.
Canada, with its rich pool of scientific talent and
commitment to research and development, has emerged as a
prominent player in the biotech arena. The country’s
biotech landscape is characterized by diverse companies
and research institutions, contributing to advancements in
areas like genomics, personalized medicine, and sustainable
bioproducts.
In the latest edition of Insights Care, we spotlight Charting
Excellence: Canada’s Top 5 Pioneers in Biotech. These
industries are at the front of innovation, steering the biotech
industry toward new horizons. These companies shape
biotechnology’s future trajectory in Canada through
dedication, strategic vision, and commitment to excellence.
In this edition, we delve into the stories of these companies,
exploring their achievements, challenges, and the impact of
their work on the biotech landscape. From groundbreaking
research to entrepreneurial understanding, these companies
exemplify the spirit of innovation that defines the Canadian
biotech ecosystem.
As we navigate through the pages, we invite you to join us
on a journey that celebrates the brilliance of biotechnology
and the pioneers propelling Canada to the forefront of this
transformative industry.
Hope you have an inspiring read ahead!
Pearl Shaw
Managing Editor

Profiles
24
BioMark Diagnostics Inc
Innovating Cancer Detection
32
BioNeutra
Bridging Science and Health
for a Better Future
Aicles
20
Minds and Machines
A Symbiotic Relationship
in Biotech Innovation
28
From Lab to Market
The Business of
Biotech Startups
Tableof
CONTENTS

Biopharma Inc.
Cer
Story
08

Copyright © 2023 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or
transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights success.
Reprint rights remain solely with Insights Success Media and Technology Pvt. Ltd. Insights Care is powered by Insights Success Media and Technology Pvt. Ltd.
December, 2023
sales@insightscare.com
Contact Us:
Follow us on : www.facebook.com/InsightsCare/ https://twitter.com/Insightscare
Insights Success Media Tech LLC
555 Metro Place North, Suite 100,
Dublin, OH 43017, United States
Phone - +1614-602-4132
Email: info@insightscare.com
For Subscription: www.insightscare.com
Insights Success Media and Technology Pvt. Ltd.
Survey No.133/134, Brand Square, Ofﬁce No. 512,
Kunjir Chowk, Pimple Saudagar, Pune,
Maharashtra 411027.
Phone - India: 7410033802, 8956487823
For Subscription: www.insightscare.com
Editor-in-Chief
Chidiebere Moses Ogbodo
Managing Editor
Pearl Shaw
Executive Editor
Natalie May
Visualiser
David King
Art & Design Head
Samuel Martinez
Co-designer
Paul Belin
Art & Picture Editor
Grace Brown
Business Development
Manager
Emily Jones
Marketing Manager
Bill Thompson
Business Development
Executives
Anna Smith, Jack Miller
Sales Executives
Mike, Carl, John
Technical Head
Jacob Smile
Assistant Technical Head
Joseph Taylor
Technical Consultants
David, Robert
Digital Marketing
Manager
Alina Sege
Assistant Digital
Marketing Manager
Daniel Jones
SME-SMO Executives
Gemson
Research Analyst
Eric Smith
Circulation Manager
James Carter
We are also available on :

Brief
Featuring
Person
Company
BioNeutra North America Inc. is a leading innovator,
dedicated to crafting high-quality and sustainable
food ingredients.
ImmunoBiochem pioneers advanced
immunotherapy solutions, contributing to cutting-
edge biomedical research and innovation.
BioMark Diagnostics Inc. innovates in cutting-
edge diagnostics, aiming to revolutionize
healthcare with advanced solutions and
breakthrough technologies.
Scimar is a Canadian company focused on
delivering marine technology solutions and
services for sustainable and efﬁcient maritime
operations.
BioNeutra North
America Inc
bioneutra.ca
Dr. Jianhua Zhu
Founder & CEO
Rashid A Bux
CEO and Founder
Anton Neschadim
CEO
Mick Lautt
CEO
BioMark Diagnostics
Inc
biomark
diagnostics.com
ImmunoBiochem
immunobiochem.com
Scimar
scimar.ca
Starpax Biopharma Inc. pioneers innovative
biopharmaceuticals, advancing
groundbreaking healthcare solutions for a
healthier future.
Michael Gareau
Founding President
starpaxbiopharma.com
Canada’s Top 5
Pioneers in
Biotech

Biopharma Inc.
Cover Story
Starpax’s
multidisciplinary
technology opens
a new era in
cancer treatment,
offering revolutionary
advancements.

Michael Gareau
Founding President
Michael Gareau
Founding President

Charting Excellence: Canada’s Top 5 Pioneers in Biotech

In the dynamic sphere of biopharmaceuticals, where
progress is measured in innovative leaps, Starpax
Biopharma Inc. emerges as a sign of innovative
solutions. The establishment is a pioneer in seamlessly
merging Microbiology, Biochemistry, Electromagnetism
Engineering and Artificial Intelligence—crafting a unique
blend of expertise that drives it into the unfamiliar domains
of scientific achievements.
At the heart of its fundamental lies a steadfast mission i.e.,
conquering the formidable challenge of cancer treatment.
Unlike conventional approaches like chemotherapy or
immunotherapy, Starpax Biopharma Inc.’s method stands
out as exceptional. Its technology navigates the
complexities of cancer, preparing for a vexing dilemma that
has perplexed scientists for years – reaching and attacking
cancer cells throughout the whole volume of the tumor,
including in hypoxic areas where are located the elusive
stem cells, a driver of metatastasis.
Starpax Biopharma Inc.’s journey is one of relentless
innovation and resolute commitment to transforming cancer
treatment. Through its interdisciplinary expertise, the
organization has unlocked novel pathways in the battle
against this formidable disease, offering a glimmer of hope
to patients and reshaping the very perspective of medical
science.
Fueling this mission is Michael Gareau, an entrepreneur
with over 40 years of experience, leading Starpax in its
pursuit to revolutionize cancer care. His priority, bring this
extraordinary technology to the patient as soon as
possible.
In this narrative, Michael shares his journey along with the
challenges he faced and outlines the organization’s strategic
vision.
Let’s delve into the insightful story of how Starpax is
becoming a leading biotech company!
Mastering Global Ventures
Michael Gareau, fortified with degrees in P. Eng., M.Sc.
Adm, and MBA from Sherbrooke University, boasts a
remarkable 41-years journey as a serial entrepreneur and
CEO in the high-technology sector.
Founder and Director of Ipax Capital led the Ipax One
Private Equity Co-investment Fund to receive accolades as
the “Top 5 best-performing buyout fund” out of 20,500
funds worldwide, recognized by London-based firm Preqin.
Gareau’s expertise shines through his leadership in over 32
Starpax PolarTrak 1000™

acquisitions across eight countries. His discerning eye for
deals led him to analyze over 20,000 opportunities in his
illustrious career, verification of his unparalleled insight
into the global business model.
In 2016, Michael stumbled upon the Virtual Monopole
Magnetic Fields patents and was captivated by their
potential. He acquired the patents and relocated to Canada
despite the challenges of bringing this innovative cancer
treatment to life. A personal tragedy fed his decision –
losing family members to cancer.
Having witnessed the devastating effects of traditional
treatments, he felt compelled to make a difference.
Motivated by a deep sense of empathy, he embarked on a
mission to develop this innovative technology, aiming to
minimize the suffering of cancer patients and transform the
circumstances of cancer treatment.
In Pursuit of a Noble Vision
Guided by an audacious mission, Starpax Biopharma Inc.
aims to revolutionize cancer treatment, with its novel
modality that would be not only highly efficient but also
remarkably gentle on patients, steering clear of debilitating
side effects. Its vision extends far and wide, aiming to
combat solid tumors, accounting for 90% of cancer cases
and 89% of cancer-related deaths.
Starpax delved into the heart of scientific innovation with
visionary zeal, acquiring two pivotal patents on virtual
monopole magnetic fields. This remarkable technology
emerged from the collaborative efforts of 188 dedicated
professionals over 17 years, laying the foundation for a
transformative approach to cancer treatment.
Embracing this challenge, Starpax embarked on a
remarkable journey, assembling a global team of more than
350 experts. This diverse and brilliant assembly of minds
converged to create a revolutionary solution, now protected
by 57 patents and pending, addressing a long-standing
resistance problem that had eluded conventional treatments
for over a century. Starpax’s evolution epitomized the
fusion of relentless determination, cutting-edge science and
a profound commitment to alleviating the suffering of
cancer patients worldwide.
Quest to Conquer the Complexities of Cancer
Despite decades of research and billions of dollars invested,
existing therapies often fail to reach every cell due to the
complex nature of tumors. In fact, multiple studies around
the world demonstrated that 90% of the volume of a tumor
receives little or no drug in systemic treatment. Tumor
heterogeneity, genetic mutations, and the ability of cancer
cells to evade treatments have posed significant hurdles.
However, a fundamental challenge lies in the hypoxic
zones, where low oxygen levels create chaos within the
blood and lymphatic vessels, hindering the delivery of
drugs.
Amid this challenge, Michael and his team at Starpax
Biopharma Inc. have pioneered a revolutionary solution.
Recognizing the limitations of conventional treatments,
they have developed a revolutionary technology designed to
reach every cancer cell throughout the entire tumor volume.
Addressing the critical issue of hypoxia, Starpax’s
innovation aims to disrupt the conventional barriers that
have impeded drug delivery and immune cell penetration.
As Michael emphasizes, “Our mission is to create a solution
that goes beyond recognizing cancer cells; it’s about
ensuring these cells are effectively targeted and eliminated.
Starpax technology navigates the complexities of hypoxic
zones, conceived to reach even the most elusive cancer
stem cells, often the drivers of metastasis.”
In the face of enduring challenges, Starpax Biopharma Inc.
has embarked on a transformative journey, striving to
redefine the cancer treatment landscape. Its radical
approach is a testimony to human ingenuity, aiming not just
to treat cancer but to eradicate it entirely.
Our Magnetodrones
are not just particles;
they’re strategic
warriors navigating
the tumor terrain.
Their aerotactic
nature, seeking out
low oxygen levels,
ensures they
penetrate the
hypoxic zones
effectively.

Revolutionizing Cancer Treatment Through Michael’s
Vision
In the fight against cancer, Starpax Biopharma Inc., led by
Michael, introduces a revolutionary solution reshaping
cancer treatment. Its innovative approach revolves around
two indispensable elements: the Magnetodrones and the
Polartrak, intricately intertwined to revolutionize cancer
therapy.
Magnetodrones, a creation of the future, are self-propelled
non-pathogenic, sensitive to specific magnetic fields,
proprietary Starpax bacterium, ingeniously engineered in
the Starpax laboratories. Each Magnetodrone bears FDA-
approved anticancer drugs on its surface, transforming it
into a targeted warrior against cancer cells. Injected directly
into the tumor, these Magnetodrones navigate the intricate
interstitial spaces of tumor tissues, seeking out cancer cells
with remarkable precision. The Magnetodrones do not
proliferate in the human body and die 60 minutes after
injection.
Guided by the Starpax Polartrak, a sophisticated medical
device, Magnetodrones are steered within the tumor by
virtual monopole magnetic fields, ensuring they reach every
nook and cranny, including the hypoxic zones, where
traditional treatments struggle to penetrate.
Michael’s vision has led Starpax to achieve extraordinary
results, as he affirms, “Our Magnetodrones are not just inert
molecule; they’re strategic living warriors navigating the
tumor terrain. Their aerotactic nature, seeking out low
oxygen levels, ensures they penetrate the hypoxic zones
effectively.” The Polartrak plays a pivotal role, enveloping
the tumor in a magnetic sphere, trapping the
Magnetodrones within the tumor, preventing them from
escaping into the rest of the patient’s body and organs in
order to preserve the patient’s well-being and forcing them
to distribute throughout the entire volume of the tumor.
In Michael’s words, “Our approach is not just scientific; it’s
a testament to our commitment to humanity. We’ve
harnessed the power of science and empathy to create a
treatment that offers hope without the fear of side effects.”
Starpax’s Magnetodrones, driven by a relentless pursuit of
excellence, have exhibited unparalleled success, boasting a
100% remission rate in preclinical trials, marking a
monumental leap toward a future free from the clutches of
cancer.
Triumphant Triumph of Cancer Conquered
In the relentless battle against cancer, Starpax Biopharma
Inc.—under Michael’s visionary guidance—pioneers a
triumphant three-pronged approach. This cutting-edge
technology offers three therapeutic benefits in a single
treatment that act like suppressing elements on cancer cells
through localized chemotherapy within the tumor,
penetrating and treating hypoxic areas while harnessing the
power of immunotherapy.
“Injecting the Magnetodrones directly in the tumor, our
therapies, guided by the PolarTrak, entrap Magnetodrones
within, preventing their escape,” Michael affirms. This
innovative technique ensures a precise attack while
minimizing impact on healthy tissues.
Highlighting this revolutionary approach to hypoxic areas,
Michael notes, “Magnetodrones accumulate within oxygen-
deprived zones where the level of oxygen is the same as
their culture medium, releasing specialized drugs to combat
non dividing stem cells.” This strategic penetration
addresses a critical aspect of cancer treatment, enhancing its
effectiveness.
Moreover, Starpax Biopharma Inc.’s therapies stimulate a
potent immune response. As Michael states,
“Magnetodrones trigger the immune system, generating
proactive immune cells. This systemic defense targets
roaming cancer cells and remote metastases, devoid of any
circulating Magnetodrones or anti-cancer drugs in the
patient’s body.”
Through these transformative methods, Starpax Biopharma
Inc. stands at the forefront of biotechnological innovation,
heralding a new era in cancer treatment.
Bridging Science and Compassion in Biotechnology
Starpax leads the charge under Michael’s visionary
guidance. With three cutting-edge laboratories and a GMP
Magnetodrones manufacturing plant, Starpax delves into
extensive research, formulating a path towards progressive
solutions. Utilizing approved drugs with expired patents,
the organization achieves remarkable precision, injecting
merely 20% of the traditional systemic chemotherapy dose
yet yielding exponential results within tumors, all while
sidestepping toxic side effects meticulously documented by
FDA and Health Canada. This strategic approach
significantly reduces clinical failure risks, elevating
Starpax’s potential to address all solid tumors representing

90% of cancer cases. The remaining 10% are that of blood
or liquid cancer like leukemia.
Moreover, Starpax’s ingenuity extends beyond cancer.
Michael illuminates the organization’s venture into non-
cancer diseases stemming from oxygen-deprived tissues.
Emphasizing the absence of blood vessels in these hypoxic
zones, he underscores Starpax’s novel approach.
“We’re exploring solutions for Ischemic heart disease,
Pulmonary hypertension, Acute Ischemic Stroke, and
Diabetic Retinopathy,” he states, describing the innovative
quest to apply existing drugs eﬀectively in these
challenging conditions where drugs cannot distribute by
themselves. With Michael at the helm, Starpax continues to
pioneer transformative treatments, reshaping the landscape
of medical possibilities.
Revolutionizing Healthcare Beyond Tradition
Michael emphasizes, “The healthcare industry needs a shift
toward science-driven solutions; single drugs and therapies
are becoming antiquated.” He notes, “Starpax’s
multidisciplinary technology opens a new era in cancer
treatment, oﬀering groundbreaking advancements.” With a
focus on advancing beyond traditional pharmaceuticals,
Starpax Biopharma Inc. is shaping the future of healthcare,
challenging established norms and leading the industry
toward innovative, science-based solutions.
Our mission is to
create a solution
that goes beyond
recognizing cancer
cells; it’s about
ensuring these cells
are effectively targeted
and eliminated.
Starpax technology
navigates the
complexities of hypoxic
zones, reaching even
the most elusive
cancer stem cells,
which are often the
drivers of metastasis.
Starpax Magnetodrones™ GMP plant

Embracing Multidisciplinary Innovation in Biotech
In his inspiring message to aspirants in biotech, Michael, a
respected figure in the industry, highlights the dawn of a
new era in therapeutic solutions. He challenges the status
quo, asserting that the traditional focus on chemical
medicines and biologics for cancer treatment is becoming
outmoded.
Instead, he advocates for the development of
multidisciplinary solutions, integrating fields like
biochemistry, microbiology, electromagnetism engineering,
and Artificial Intelligence. Drawing from Starpax’s
pioneering work in cancer treatment, Michael envisions a
future where therapeutic companies mirror the innovation
of tech giants. He emphasizes the need for emerging leaders
to embrace diverse scientific disciplines, heralding a
paradigm shift that will shape the industry’s future.
Pioneering Healthcare Access Through Strategic
Expansion
In envisioning the future of Starpax Biopharma Inc.,
Michael underscores the organization’s meticulous strategic
approach. Having rigorously evaluated numerous
commercial solutions to expedite patient access, Starpax
has been collaborating with esteemed partners, including a
top-tier accounting firm and expert consultants in the
United States. The culmination of this analysis led to the
visionary creation of Starpax Cancer Centers (SCC) in the
USA. Each SCC, equipped with advanced medical
facilities, Starpax Polartrak rooms and staffed by dedicated
professionals, marks a significant stride in Starpax’s
mission.
Crucially, the organization has embarked on a collaboration
with a renowned multinational corporation in the field of
healthcare development, poised to construct and deliver
Starpax’s evolution
epitomized the
fusion of relentless
determination,
cutting-edge science
and a profound
commitment to
alleviating the
suffering of cancer
patients worldwide.
turnkey SCCs. With an addressable market for 580 centers
in the USA (and 1200 including Europe), Starpax
anticipates a rapid deployment, ensuring widespread access
to its state-of-the-art solutions. As highlighted in previous
insights, the vast market potential positions Starpax as a
formidable industry player, heralding a future where
innovation and accessibility converge seamlessly.
Starpax is in fundraising now to cover the cost of its
clinical trials on human. See in at
www.investinstarpax.com

n the ever-evolving field of biotech innovation, a
Ipowerful partnership is unfolding between human
intellect and advanced machines. This collaboration,
driven by practical needs and fueled by mutual benefits, is
reshaping the landscape of scientific progress. In the complex
world of biotechnology, the interplay between human minds
and cutting-edge machines is proving to be a driving force,
propelling us towards unprecedented breakthroughs.
Let’s embark on a journey exploring the dynamic
collaboration between human intellect and advanced
machines in shaping biotech innovation!
Human Expertise—The Driving Force in Biotech
Biotechnological breakthroughs are rooted in the expertise of
human scientists. Understanding biological systems,
molecular structures, and intricate cellular processes requires
the nuanced knowledge and creative problem-solving abilities
inherent in the human mind. The complexity of biological
entities demands a level of comprehension that only human
intelligence can provide.
Researchers and biotechnologists, committed to solving the
mysteries of life, embark on a journey to expand scientific
knowledge. Their expertise acts as a guiding light, steering the
industry towards solutions for critical challenges, such as
developing new therapies and addressing environmental
concerns.
The Rise of Machines—A Practical Ally
As the demands on biotechnology grow, integrating machines
into the research and development process has become
essential. Machines, driven by artificial intelligence (AI) and
www.insightscare.com
December 2023 20
ASymbiotic
Relationship
inBiotech
Innovation

December 2023
Minds and Machines
21

machine learning algorithms, bring unique capabilities to
the table. Their ability to process vast amounts of data,
identify patterns, and make predictions at incredible speeds
complements human researchers' strengths.
Machines play a crucial role in data analysis, especially
with the explosion of biological data from various omics
technologies. They excel at sifting through extensive
datasets, extracting relevant information, and providing
valuable insights that shape the direction of experiments. In
drug discovery, machine learning algorithms analyze
molecular structures, accelerating the research and
development pipeline and bringing life-saving treatments to
patients more efficiently.
Automating Laboratory Workflows
Machines are also being integrated into laboratory
workflows to automate repetitive tasks. Robotic systems
equipped with precision instruments conduct experiments
with a level of accuracy and reproducibility that surpasses
human capabilities. This not only speeds up the research
process but also reduces the likelihood of human error,
significant for reliable experimental results.
The integration of automation allows researchers to focus
on tasks that require creative thinking and problem-solving.
By offloading routine laboratory work to machines,
scientists can dedicate more time to designing experiments,
interpreting results, and formulating innovative hypotheses.
Challenges and Ethical Considerations
While the collaboration between humans and machines
holds promise, it comes with challenges. Ethical
considerations surrounding the use of AI in biotechnology,
including issues related to data privacy, bias in algorithms,
and responsible technology use, must be carefully
addressed.
The rapid pace of technological advancement demands a
commitment to education and upskilling within the biotech
workforce. Researchers and professionals must stay
updated on the latest developments in AI and machine
learning to use these tools effectively and responsibly.
The Future—A Collaborative Ecosystem
Looking ahead, the future of biotech innovation is likely to
be defined by a collaborative ecosystem where human
intelligence and machine capabilities seamlessly work
together. AI integration is expected to extend beyond the
laboratory, influencing decision-making processes across
the biotech industry, from research and development to
regulatory affairs.
In drug development, AI-driven simulations may become
instrumental in predicting the safety and efficacy of new
compounds. Regulatory agencies may leverage machine
learning algorithms to analyze vast amounts of data,
streamlining the approval process for new therapies. The
possibilities are extensive, and as the partnership between
humans and machines matures, the biotech landscape will
undergo transformative changes.
A Holistic Approach—Balancing Technology and
Human Touch
In the pursuit of biotech innovation, maintaining a holistic
approach is essential. While machines offer unparalleled
efficiency and data processing capabilities, the human touch
remains irreplaceable. The intuitive understanding,
creativity, and ethical judgment that humans bring to the
table are crucial elements in ensuring that technological
advancements align with societal values and ethical
standards.
Conclusion
In the realm of biotech innovation, the collaboration
between human minds and machines is reshaping the
landscape of scientific discovery. Human expertise provides
the essential foundation, guiding the industry with a deep
understanding of biological systems. Simultaneously,
machines, with their computational prowess and efficiency,
propel the field forward, accelerating the pace of discovery
and revolutionizing traditional approaches.
Standing at the intersection of human ingenuity and
technological advancement, the harmonious collaboration
between humans and machines, maintaining a holistic
approach, holds the key to unlocking the next wave of
biotechnological breakthroughs. With ethical considerations
at the forefront and a commitment to ongoing education, the
biotech industry is poised to harness the full potential of
this collaborative relationship, ushering in a new era of
innovation and progress.
Pearl Shaw
December 2023 22

dynamic field like diagnostics requires efficient
Atechnologies for detecting diseases and critical
illnesses. One organization that stands out with its
innovative solutions in pursuit of this universal mission is
BioMark Diagnostics Inc.
It is an oncology-focused company that provides early-
stage cancer detection, monitoring, and screening solutions
for hard-to-detect cancers using liquid biopsy. It uses
metabolomic fingerprinting to detect early-stage cancer.
Rashid Bux, Founder and CEO at BioMark, holds a
unique blend of scientific and business expertise. Leading
the company since 2013 he has been instrumental in the
development and commercialization of BioMark’s
technology.
We at Insights Care spoke with Rashid to learn more about
BioMark and how it stands apart from other organizations:
Briefly introduce yourself and share a few significant
details about your professional tenure.
My name is Rashid Bux. I grew up in Kenya, East Africa
where I attended Nairobi University prior to going to North
America to advance and complete my education. I have
both a scientific and business orientation which comes in
handy, especially navigating in the biotechnology space.
Early in my career I developed and ran a sustainable energy
enterprise called Homeworks and later launched the Earth
Advantage Brand at Portland General Electric. These
ventures were focused on encouraging and facilitating
energy efficiency and conservation on a broad scale
leveraging utilities (Gas and Electric); retail (Home Depot),
Banks (non-secured financing for consumers to
upgrade/retrofit their homes.
What inspired you to venture into biotech?
Cancer has impacted my family directly. My oldest brother
died of lung cancer because it was detected at a late stage.
He was a mechanic and a smoker and served in the army for
a few years before working for a car company, which most
likely contributed to his condition. He passed away in 2011.
My elder sister died of cervical cancer in England in 2007.
My younger sister’s breast cancer metastasized to her brain.
She passed away last July after undergoing treatment in
London, England. My family friend has a daughter, age 25,
who was recently diagnosed with pancreatic cancer.
Kenya like many developing nations access to quality
health care is a challenge. Developing an affordable
minimally invasive and accurate test could be a game-
changer in communities that have large disparities in
healthcare provisioning.
Give a brief overview of BioMark Diagnostics Inc.
BioMark is a North American life sciences company that
has developed a state-of-the-art liquid biopsy platform for
the early detection of hard-to-detect and treat cancers such
as lung, pancreatic and brain (GBM). We are developing the
next generation of molecular diagnostic solutions using
biomarkers and incorporating machine learning algorithms.
Our customers include lab operators, hospitals that have
operating labs, and community hospitals that are under-
resourced.
What are its mission and vision statements?
Our driving purpose is to work with a network of
biopharma partners, clinicians, lab operators, multi-
disciplinary research, data scientists and regulators to help
conquer cancer. Cancer is a global and complex disease that
BioMark
Diagnostics Inc
Charting Excellence: Canada's Top 5 Pioneers in Biotech
December 2023 24

requires a concerted effort to truly reduce incidence rates,
better manage the disease, and finally eradicate it.
What are some of the unique aspects that set your
organization apart from other biotech companies?
Ÿ Excellent Diagnostic Confidence
The accuracy of our assays provides excellent diagnostic
confidence. In addition, the metabolic-based signatures our
tests can detect cancers before patients show symptoms.
This literally translates to early interventions, improving
survival rates significantly.
Ÿ Cost efficiency
BioMark’s platform leverages high-throughput systems
with robotic sample handling capabilities, making mass-
scale screening viable without compromising accuracy or
speed.
1. Invest and build high payoff capabilities/platforms to
drive diagnostic breakthroughs.
2. Support sustainable development goals related to climate
change impact on health – SDG3.4.
3. Offer scalable solutions – that overcome challenges such
as geography, distribution, and economies of scale to create
impactful, timely, and equitable solutions.
4. Be a proactive health provider - reduce the likelihood
that people become patients and create new capabilities to
detect and characterize disease risk to promote viable
treatment options.
5. Building resiliency in healthcare systems to ensure
effective healthcare delivery; Better weather crises from
molecular to societal crises; achieve outcomes that enhance
health and well-being.
BioMark’s technology is revolutionizing cancer
management through:
Ÿ Early Detection: By utilizing cutting-edge technology,
BioMark enables the early detection of cancer markers,
providing clinicians with crucial information for timely
intervention.
Ÿ Precision Medicine: Our tools offer precise molecular
profiling, allowing for tailored treatment plans that
maximize efficacy and minimize side effects.
Ÿ Serial Monitoring: BioMark’s solutions provide
monitoring of cancer progression, offering both patients
and healthcare providers invaluable insights for
proactive decision-making.
Ÿ Data-Driven Insights: Through advanced analytics and
AI, BioMark translates complex data into actionable
insights, empowering healthcare professionals with
evidence-based strategies.
Ÿ Help reduce diagnosis to treatment time in cancer
management.
Ÿ Improved Patient Outcomes: Ultimately, BioMark’s
tools lead to improved patient outcomes, enhancing both
the quality and length of life for those battling cancer.
What role is your organization playing in shaping
Canada’s biotech landscape?
Ÿ Disrupting the cancer diagnosis and management
paradigm by investing in right technologies, building a
dynamic team with a customer empathy culture,
willingness to adopt new technologies, and grit to reach
the endpoint.
Ÿ Building a resilient and agile organization that can help
deliver exceptional cancer diagnostic e solutions to
underserved and resource-challenged communities.
Ÿ Encouraging a Pan-Canadian collaboration across
multiple disciplines.
December 2023 25

Ÿ Building and showcasing our solutions with leading
institutions and clinicians to facilitate faster adoption of
our diagnostic technology platform.
Ÿ Partnering with leading biopharma partners such as
AstraZeneca and Pfizer demonstrate that Canada offers a
favorable investment environment for innovation and
R&D in biotechnology. We are on target to complete a
4,000 multimodal early lung cancer study involving 7
hospitals across Quebec, IUCPQ, Pfizer and
AstraZeneca by the end of Q4.
Ÿ Fostering and developing research and business
collaborations with leading institutions across the US.
How does the company stay updated with the latest
biotechnological advancements?
Ÿ Reading Leading Journal
Ÿ Presenting at leading Oncology-focused seminars and
symposiums such as ASCO; USCAP; San Antonio
Breast Cancer Symposium etc
Ÿ Publishing in journals and keeping in touch with editors.
Ÿ Being part of patient advocacy groups
Ÿ Being members of oncology associations
Ÿ GenomeWeb
Ÿ 360Dx
Ÿ Presenting and meeting investors and companies at
biotech events
Ÿ Equities.com
Ÿ Wallstreet – health and technologies
Ÿ Monthly internal meetings – market scan sessions
Ÿ Talking to biopharma partners – understanding their
pipeline challenges
What are some of the most significant challenges that
your organization has faced and what strategies have
helped in navigating them?
Ÿ Being black (minority) has been a challenge to raise
capital in both the US and Canada despite all the talk of
levelling the economic playing field. I have been
fortunate to have patient individual investors over the
years. The lack of sufficient capital slowed our
commercialization velocity and reduced our scale-up
aspirations. My advisory board members are busy trying
to open investor doors for the company.
Ÿ As we plan to launch our early lung detection blood-
based assay in Q4 of this year we believe there will be
many folks who might have a renewed interest in
investing in our company.
What advice would you give to budding professionals
who wish to venture into this dynamic industry?
Have patience, courage, and be prepared for a long journey.
Build a vibrant network, especially for capital raising and
knowledge sharing.
Remain curious and develop a culture of experimentation.
Finally, harness technology to enhance your core business.
What vision do you hold for the future of your
organization in the coming years?
A fully integrated Omics diagnostic company with
advanced analytics capabilities that offers dynamic cancer
management solutions on a global basis.
December 2023 26

From Lab to Market
December 2023 28

The world of biotech startups is a dynamic frontier where
scientific innovation meets entrepreneurial spirit. In this
landscape, the journey from the laboratory to market
success is both thrilling and challenging.
Let's delve into the intricacies of the business of biotech
startups, exploring how these ventures transform
groundbreaking research into viable products that can make
a real impact.
The Genesis—From Lab Discovery to Startup
Biotech startups typically emerge from the fertile grounds
of research laboratories. Here, scientists and researchers
delve into the complexities of biology, seeking solutions to
medical, agricultural, or environmental challenges. When a
promising discovery takes root, the transition from lab to
startup begins.
The initial phase involves translating scientific findings into
a viable business concept. Researchers often collaborate
with business-savvy professionals to assess market potential
and devise a strategy for commercialization. It's a critical
juncture where scientific merit meets economic viability.
Securing Funding—The Lifeblood of Biotech Startups
Turning a lab discovery into a market-ready product
requires substantial financial support. Biotech startups
navigate a complex funding landscape that includes grants,
venture capital, and strategic partnerships. Securing funding
is a pivotal step, allowing startups to conduct further
research, develop prototypes, and move closer to market
entry.
The regulatory hurdles in the biotech industry add an extra
layer of complexity. Startups must allocate resources to
navigate regulatory pathways, ensuring compliance with
standards and protocols. This process is time-consuming
but essential for bringing safe and effective products to
market.
Research and Development—Bridging the Gap
Research and development (R&D) form the backbone of
biotech startups. This phase involves refining discoveries,
optimizing processes, and developing scalable production
methods. It's a journey marked by iterative experimentation,
setbacks, and, ultimately, progress toward a market-ready
product.
December 2023 29
TheBusiness
ofBiotech
Startups

Biotech startups must strike a delicate balance between
innovation and practicality during R&D. While pushing the
boundaries of science is crucial; the end goal is to create a
product that addresses a real-world need and can be
produced at a scale that makes economic sense.
Building a Team—The Human Element
The success of a biotech startup relies heavily on
assembling a talented and diverse team. Scientists bring
technical expertise, while business professionals contribute
strategic acumen. The intersection of these skills fosters an
environment where scientific breakthroughs align with
market dynamics.
In addition to technical and business skills, communication
and collaboration are paramount. A cohesive team can
navigate the complex terrain of biotech entrepreneurship,
from securing partnerships to communicating with investors
and regulatory authorities.
Market Entry—Challenges and Opportunities
As a biotech startup approaches market entry, it faces a
myriad of challenges. Competition is fierce, and gaining
market share requires effective positioning and marketing
strategies. Startups must also consider pricing models,
distribution channels, and customer education.
Partnerships with established companies can provide
valuable support during market entry. These collaborations
offer access to established distribution networks, regulatory
expertise, and additional funding. Striking the right
partnerships can significantly enhance a biotech startup's
chances of success.
Scaling Up—Manufacturing and Distribution
Successfully navigating the transition from lab-scale
production to large-scale manufacturing is a critical
milestone for biotech startups. This phase requires
significant investment in infrastructure, quality control
processes, and supply chain management.
Manufacturing challenges can arise, impacting the
consistency and quality of the product. Addressing these
challenges swiftly is essential to meet market demand and
maintain the trust of consumers and stakeholders.
The Role of Innovation in Sustaining Growth
In the fast-paced world of biotech, sustained growth relies
on ongoing innovation. This innovation extends beyond
product development to include improvements in
manufacturing processes, cost reduction strategies, and
adaptation to evolving market needs.
Biotech startups must remain agile, responsive to emerging
trends, and willing to embrace new technologies.
Continuous innovation not only strengthens a startup's
market position but also enhances its resilience in the face
of competition and changing industry dynamics.
Navigating Challenges—Lessons Learned
The journey of a biotech startup is riddled with challenges,
but each obstacle presents an opportunity for learning and
adaptation. Whether it's a regulatory setback, manufacturing
hurdle, or market competition, successful startups leverage
these experiences to refine their strategies and strengthen
their resilience.
Flexibility and a willingness to pivot are essential traits for
biotech entrepreneurs. Adapting to unforeseen
circumstances, seizing opportunities, and learning from
failures contribute to the long-term success of a biotech
startup.
Conclusion—The Ever-Evolving Biotech Landscape
The business of biotech startups is a multi-faceted journey
that demands a harmonious blend of scientific acumen and
entrepreneurial spirit. From the lab to market success,
startups navigate complex terrain, overcoming challenges,
securing funding, and bringing innovative solutions to the
world.
As biotech continues to play a pivotal role in addressing
global challenges, the success of startups will be
instrumental in driving positive change. The lessons learned
from these ventures contribute not only to the growth of
individual companies but also to the collective knowledge
of the biotech industry, shaping the future of scientific
innovation and market dynamics.
Pearl Shaw
December 2023 30

Dr. Jianhua Zhu
Founder & CEO
BioNeutra North America Inc.
December 2023 32

C
anada’s biotech sector thrives at the intersection of
science and technology, where innovations tackle
diseases in a dynamic landscape. Among the
standout companies in this thriving industry, BioNeutra
North America Inc. distinguishes itself with its innovative
offerings. As an agri-biotechnology manufacturer, it
specializes in patented technology, producing natural fiber
sweeteners and food ingredients.
Founded in 2003 by Jianhua Zhu, a seasoned expert in
starch and carbohydrate chemistry, BioNeutra benefits from
his extensive scientific and technical knowledge. Prior to
BioNeutra, Mr. Zhu held positions as a professor at the
University of Alberta and as a Senior Scientist at Edmonton
Biotech.
At the heart of BioNeutra’s offerings is VitaFiber® IMO, an
advanced functional food and beverage ingredient derived
from natural agricultural products. Recognized as safe by
the U.S. FDA, approved as a novel fiber by Health Canada,
and acknowledged as a novel food ingredient by the
European Food Safety Authority, VitaFiber® IMO offers a
natural, low-calorie alternative to sugar, doubling as a
source of dietary fiber and prebiotics for digestive health.
Inspired by a family legacy in public health, Mr. Zhu’s
dedication to improving well-being led him on a path to
develop health-enhancing ingredients.
Insights Care interacted with Mr. Zhu to uncover intriguing
details about BioNeutra and his contributions to the
organization’s growth and development.
Give a brief overview of your organization. What are its
mission and vision statements?
BioNeutra Global Corporation (TSX.V: BGA), based in
Edmonton, Alberta, is a publicly traded health & nutrition
ingredients and agriculture value-added company. The
Company is listed on the Canadian Securities Exchange
(the “CSE”) under the symbol “BGA”.
Through its wholly owned subsidiaries, BioNeutra North
America Inc. and BioNeutra International Limited, the
Company is in the business of research and development,
production and commercialization of ingredients for
nutraceutical, functional and mainstream foods and
beverages. BioNeutra’s current focus involves developing
and manufacturing a line of natural products targeting the
multi-billion-dollar mainstream and functional food
ingredients markets.
What are some of the unique aspects that set your
organization apart from other biotech companies?
BioNeutra was the first company in North America to
develop and manufacture isomalto-oligosaccharides (IMO).
BioNeutra also was the first company to obtain regulatory
approval for its IMO as a novel fiber in Canada, GRAS
ingredient in the US and novel food in Europe. As a lead
innovator in IMO’s, BioNeutra was able to establish both
the North American and European markets for this product.
VitaFiber® is known around the world as the premier,
specialized IMO that is backed by multiple scientific studies
– and we continue to conduct new research into this
product.
BioNeutra
Bridging Science and Health
for a Better Future
Charting Excellence: Canada’s Top 5 Pioneers in Biotech
December 2023 33

Our manufacturing plant is equipped with state-of-the-art
equipment that has the capacity to process up to 200MT of
starch/month. Other unique aspects that set BioNeutra apart
from its competitors include certifications of its
manufacturing plant: we are certified as Halal, Kosher, non-
GMO, and organic and hold quality assurance FSSC 22000
certifications. Additional differentiators include the
availability of corn, tapioca and pea based IMOs. BioNeutra
is the only company in the world that produces isomalto-
oligosaccharides using pea starch.
What role is your organization playing in shaping
Canada’s biotech landscape?
BioNeutra developed a unique patented process that uses
locally sourced starch and converts it into isomalto-
oligosaccharides. IMO consist of a mixture of non-
digestible oligosaccharides of DP between 2-7. Several
experimental and clinical studies have demonstrated that
IMO mixtures are not completely digested by gut enzymes
are exhibit prebiotic properties2-4. IMOs are used in the
food industry as high fiber and low-calorie syrup that
provides several health benefits including prebiotic effects.
Using a natural enzymatic process, we transform starch
molecules from these crops into the value-added functional
health molecules of IMO. The company uses pea starch to
make VitaFiber IMO. Peas are one of the only plants that
add nitrogen back into soil and therefore are considered a
more sustainable crop. We are beginning to see that locally
produced pea IMO – and particularly organic pea IMO – is
being very well received in the North American market.
How does the company stay updated with the latest
biotechnological advancements?
The company’s scientific team consists of 6 Ph.D.’s, and are
experts in nutrition, biochemistry, and food science. The
team remains updated with the latest biotechnological
advancements by performing regular literature searches,
attending conferences and networking with experts in the
field. BioNeutra has also collaborated with several
university professors to perform studies to determine
mechanisms of action and enhancements of its products2-5.
The collaboration also helps the team to stay updated with
the latest research carried out in the relevant areas.
What are some of the most significant challenges that
your organization has faced and what strategies have
helped in navigating them?
Although IMO are considered a dietary fiber in Canada,
they are only recognized as a GRAS ingredient in the US.
BioNeutra submitted two petitions to the US-FDA to
consider IMO as a dietary fiber, both were rejected. The
rejection affected the company’s revenues. The company
has now started R&D work to develop other high fiber
syrups that could be considered dietary fiber globally
including the US.
The functional food and beverage industry is characterized
by competition and ongoing product development in all its
phases. VitaFiber competes with numerous other products
within similar food and beverage ingredient products.
Competitive factors in the manufacturing and sale of
functional food and beverage product ingredients include
price, methods of production, and the ability to deliver
products to the market. BioNeutra needs to ensure that its
Our vision is to make BioNeutra
the world leader in the production
of innovative and high-quality
nutritional ingredients for the
continuously evolving food
and beverage, nutraceutical,
and functional food industry.
December 2023 34

products remain competitive in the marketplace, otherwise
the company’s future growth can be negatively impacted.
What advice would you give to budding professionals
who wish to venture into this dynamic industry?
Consumers are becoming increasingly health conscious and
seek foods that are enriched with bioactive ingredients that
are beneficial to human health. Cost also plays an important
factor in their food selection. Therefore, professionals who
want to venture in the industry of functional foods and
beverages, must ensure that their products are innovative,
provide health benefits, meet regulatory requirements and
are affordable to today’s consumers.
What vision do you hold for the future of your
organization in the coming years?
Our vision is to make BioNeutra the world leader in the
production of innovative and high-quality nutritional
ingredients for the continuously evolving food and
beverage, nutraceutical, and functional food industry. Since
the world of fibre demand is growing, we are seeing a
upswing in this industry, and particularly as a food,
nutritional supplement company to help people, reduce
sugar content in production facilities of consumer products,
as well as growing the fibre component in foods that we
need in our bodies. Market demand around the world is
echoing these thoughts, and we are positioning ourselves to
be a world leader in this field.
December 2023 35

Stay in Touch.
Subscribe to Insightscare Get Insights Care
Magazine in print, & digital on
Corporate Ofﬁce
Insights Success Media Tech LLC
555 Metro Place North, Suite 100,
Dublin,OH 43017, United States
Phone - (614)-602 - 1754,(302)-319-9947
For Subscription : www.insightscare.com
Cheque should be drawn in favor of :
INSIGHTS SUCCESS MEDIA TECH LLC

Charting Excellence Canada’s Top 5 Pioneers in Biotech 1.pdf

Charting Excellence Canada’s Top 5 Pioneers in Biotech 1.pdf

Recommended

Recommended

More Related Content

Similar to Charting Excellence Canada’s Top 5 Pioneers in Biotech 1.pdf

Similar to Charting Excellence Canada’s Top 5 Pioneers in Biotech 1.pdf (20)

More from insightscare

More from insightscare (20)

Recently uploaded

Recently uploaded (20)

Charting Excellence Canada’s Top 5 Pioneers in Biotech 1.pdf